All In Biotech

NDA 208289 · Exela Pharma

Akovaz

Ephedrine Sulfate · Intravenous

Last checked: Nov 20, 2026Latest source record: Aug 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 29, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

201

29 Phase 3, 14 recruiting

FAERS reports

162

117 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 27, 2020.

AKOVAZ (ephedrine sulfate injection) is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. AKOVAZ injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. ( 1 )

Mechanism: Ephedrine sulfate is a sympathomimetic amine that directly acts as an agonist at α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic stimulation is caused by norepinephrine release from sympathetic nerves.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AKOVAZ · EPHEDRINE SULFATE 25MG/5ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP3
  • AKOVAZ · EPHEDRINE SULFATE 50MG/ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ephedrine" as an intervention, any sponsor and status, largest first.

All 201 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective25
  • drug abuse14
  • cardiac arrest13
  • toxicity to various agents13
  • overdose12
  • respiratory arrest11
  • administration related reaction10
  • hypotension10
  • no adverse event10
  • off label use10
  • drug hypersensitivity9
  • nausea8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20064
20084
20092
20106
20112
20121
20131
20144
20151
20165
20178
201820
201913
202010
202115
20228
202317
202418
202513
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 848 on PubMed

Sponsor: Exela Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.